» Articles » PMID: 19861701

Treatment of Full-thickness Chondral Defects with Hyalograft C in the Knee: a Prospective Clinical Case Series with 2 to 7 Years' Follow-up

Overview
Journal Am J Sports Med
Publisher Sage Publications
Specialty Orthopedics
Date 2009 Oct 29
PMID 19861701
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tissue engineering has become available for cartilage repair in clinical practice.

Hypothesis: The treatment of full-thickness chondral defects in the knee with a hyaluronan-based scaffold seeded with autologous chondrocytes provides stable improvement of clinical outcome up to 7 years.

Study Design: Case series; Level of evidence, 4.

Methods: Fifty-three patients with deep osteochondral defects in the knee were treated with Hyalograft C. The mean age at implantation was 32 +/- 12 years, the mean defect size was 4.4 +/- 1.9 cm(2), and the mean body mass index was 24.5 +/- 3.8 kg/m(2). Implantations were performed with miniarthrotomy or arthroscopy. The primary indications for implantation with Hyalograft C included young patients with a stable joint, normal knee alignment, and isolated chondral defects with otherwise healthy adjacent cartilage. The secondary indications were patients who did not meet the primary indication criteria or were salvage procedures. Forty-two patients with primary indications and 11 patients with secondary indications were evaluated. Outcome was evaluated with the International Cartilage Repair Society and International Knee Documentation Committee scales, the Lysholm score, the modified Cincinnati score, and with Kaplan-Meier survival analysis. Statistical analysis consisted of bivariate correlation analysis and unpaired, 2-tailed t tests.

Results: A highly significant increase (P <.001) in all knee scores was found in patients treated for the primary indications. Nine of 11 secondary indication cases underwent total knee arthroplasty due to persisting pain between 2 and 5 years after implantation. Graft failure occurred in 3 of 42 patients with primary indication between 6 months and 5 years after implantation. Kaplan-Meier survival demonstrated significantly different chances for survival between primary and secondary outcome and between simple, complex, and salvage cases, respectively (P <.001).

Conclusion: Hyalograft C autograft provides clinical improvement in healthy young patients with single cartilage defects. Less complicated surgery and lower morbidity are considered advantages of the technique. The results of treatment with Hyalograft C as a salvage procedure or in patients with osteoarthritis are poor.

Citing Articles

Low-intensity pulsed ultrasound promotes mesenchymal stem cell transplantation-based articular cartilage regeneration via inhibiting the TNF signaling pathway.

Chen Y, Yang H, Wang Z, Zhu R, Cheng L, Cheng Q Stem Cell Res Ther. 2023; 14(1):93.

PMID: 37069673 PMC: 10111837. DOI: 10.1186/s13287-023-03296-6.


Within or Without You? A Perspective Comparing In Situ and Ex Situ Tissue Engineering Strategies for Articular Cartilage Repair.

OConnell C, Duchi S, Onofrillo C, Caballero-Aguilar L, Trengove A, Doyle S Adv Healthc Mater. 2022; 11(24):e2201305.

PMID: 36541723 PMC: 11468013. DOI: 10.1002/adhm.202201305.


Progress and prospect of technical and regulatory challenges on tissue-engineered cartilage as therapeutic combination product.

Guo X, Ma Y, Min Y, Sun J, Shi X, Gao G Bioact Mater. 2022; 20:501-518.

PMID: 35846847 PMC: 9253051. DOI: 10.1016/j.bioactmat.2022.06.015.


[Autologous chondrocyte transplantation with bone augmentation for the treatment of osteochodral defects of the knee : Treatment of osteochondral defects of the femoral condyles using autologous cancellous bone from the iliac crest combined with...].

Stotter C, Nehrer S, Klestil T, Reuter P Oper Orthop Traumatol. 2021; 34(3):239-252.

PMID: 34842942 PMC: 9197922. DOI: 10.1007/s00064-021-00751-6.


Clinical Application Status of Articular Cartilage Regeneration Techniques: Tissue-Engineered Cartilage Brings New Hope.

Jiang S, Guo W, Tian G, Luo X, Peng L, Liu S Stem Cells Int. 2020; 2020:5690252.

PMID: 32676118 PMC: 7345961. DOI: 10.1155/2020/5690252.